Biopharma EHS
This episode is a test use case where you can take a very technical scientific document and upload to a large language model to create a two-host podcast. The results were amazing.
info_outlineBiopharma EHS
In this episode, Dean Calhoun of Affygility Solutions discusses top 10 mistakes & tricks used by cheap providers of PDE reports.
info_outlineBiopharma EHS
Interview with Mark Cunningham-Hill where we will discuss the coronavirus and precautions that business travelers should take and other precautions in general when traveling on business internationally.
info_outlineBiopharma EHS
In this episode, Dean Calhoun of Affygility Solutions interviews Dave Eherts, Vice President of Global EHS for Allergan. In this 25 minute interview we discuss a wide variety of EH&S issues that Dave was involved in over his 30+ years in EHS. These issues include managing the financial aspects of EHS, potent compound safety and the challenges with occupational exposure limits for pharmaceuticals, and other career advice for EH&S professionals.
info_outlineBiopharma EHS
For July 20, 2017. Artificial Intelligence is about to play a major role in the pharmaceutical industry. On July 2nd of this year, Glaxo-Smith-Kline revealed a 43-million dollar deal in which they will use A.I. to make the process of discovering new drugs easier. The goal is to reduce the time it takes from identifying a target for disease intervention to finding a molecule that acts against it. He hopes to bring it from an average 5 and a half years today to just one year in the very near future.
info_outlineBiopharma EHS
Occupational Toxicology and Occupational Medicine - Where are they the same and where are they different? In this episode of the BioPharma EHS Podcast, Dean M. Calhoun, President and CEO of Affygility Solutions hosts a discussion between Dr. Mark Cunningham-Hill, President of Worldwide Health Consulting LLC and Dr. Frank Richardson, Principal Toxicologist for LLC. The discussion starts out covering the basic elements of an occupational medicine program and the unique challenges posed by the pharmaceutical industry in which occupational exposure to potent compounds can cause adverse effects in...
info_outlineBiopharma EHS
In Episode #24 of the Biopharma EHS podcast, Dean M. Calhoun, CIH discusses with Dr. Joe Nieusma, Senior Occupational Toxicologist for Affygility Solutions, the "Mystery of Cytotoxic Compounds." For multi-product pharmaceutical manufacturing facilities, this often a controversial topic since many people believe that cytotoxic compounds require dedicated facilities or equipment. It is also a topic of debate when setting occupational exposure limits and acceptable daily exposure values for active pharmaceutical ingredients.
info_outlineBiopharma EHS
In this episode of the Biopharma EHS podcast, Dean M. Calhoun, CIH, President and CEO of Affygility Solutions interviews Kevin Rosenthal of . During the interview we discuss handling potent compounds, , and occupational control banding.
info_outlineBiopharma EHS
In this episode of the Biopharma EHS Podcast, Dean M. Calhoun, CIH, President and CEO of , interviews Ms. Stephanie Wilkins, President of , on the subject of Risk-MaPP, ADEs and PDEs: Their importance to multi-product pharmaceutical manufacturing facilities. Risk-MaPP stands for Risk-Based Manufacture of Pharmaceutical Products. It is one of the International Society of Pharmaceutical Engineers' (ISPE) Base-line Guides. One of the essential components of Risk-MaPP is the determination of acceptable daily exposure (ADE) values. Calculation of ADEs is similar to the calculation of PDEs presented...
info_outlineBiopharma EHS
BioPharma EH&S Podcast Episode No. 20...
info_outlineBioPharma EH&S Podcast Episode No. 20
Hello everybody and welcome back to another Episode of the BioPharma EH&S Podcast, my name is Dean Calhoun of Affygility Solutions and this is the podcast dedicated to discussing critical environmental, health and safety issues facing the biopharma industry, helping you take your environmental, health and safety programs to the next level.
First, I’ll briefly cover what we talked about last time in episode number 19
Then I will cover our main topic for today, which is EH&S Software – The Challenge of User Adoption
And finally, we’ll discuss upcoming events and happenings of importance to environmental, health and safety professionals in the BioPharma Industry.
So, let’s go ahead get started. Last time in Episode number 19 we discussed the topic of “The Future of Potent Compound Safety – the next 100 years.” In that Podcast, I presented four emerging trends that will shape the future of the pharmaceutical industry. Those trends included first, the development of medicines in space; second, the trend called “the Internet of Things;” third, the Maker Movement; and forth and finally, the Use of Big Data Tools. If that’s something that may interest you, I would suggest that you go back and listen to Episode 19.
Alright, let’s now move on to our main topic for today which is EHS software – the challenge of user adoption. So without further delay, here we go.
- Measure usage;
- Ensure data quality;
- Engage users during meetings;
- Tie individual compensation to usage; and
- Use peer pressure.
In addition to those five suggestions listed above, I would like to provide some additional suggestions. These additional suggestions include:
- Ensure executive leadership involvement;
- Identify and reward super users;
- Perform floor-walking;
- Ensure that the EHS software system is used by taking the approach, "If it isn't in the EHS software system, it didn't happen;"
- Mandate both timeliness and data quality.
O.k., that does it for our main topic, let’s now talk about some upcoming events.
Alright that does it for our main topic this week. One additional item that I would like to remind everyone of is oelfastrac.com, which is a convenient and affordable way to obtain high-quality occupational exposure limit monographs for common APIs. To learn more, please go to oelfastrac.com.
That does it for this week’s show. We look forward to having you listen in next time.
Have a great rest of the day.